GILEAD SCIENCES SL
- Country
- 🇪🇸Spain
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials
- Conditions
- First Posted Date
- 2015-07-29
- Last Posted Date
- 2023-01-27
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 461
- Registration Number
- NCT02510300
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
Study to Evaluate the Pharmacokinetics of Selonsertib in Participants With Normal and Impaired Hepatic Function
- First Posted Date
- 2015-07-28
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 52
- Registration Number
- NCT02509624
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 255
- Registration Number
- NCT02487030
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
- First Posted Date
- 2015-06-24
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 107
- Registration Number
- NCT02480712
Utilization and Efficacy of Tenofovir DF in Adolescents With Chronic Hepatitis B Virus Infection
- First Posted Date
- 2015-06-24
- Last Posted Date
- 2019-05-20
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT02479880
- Locations
- 🇬🇷
Attikon General Hospital Of Athens, Chaidari, Greece
🇫🇷Hopital Femmes Meres Enfants, Bron, France
🇮🇹Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection
- First Posted Date
- 2015-06-16
- Last Posted Date
- 2018-11-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 153
- Registration Number
- NCT02472886
Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2015-06-11
- Last Posted Date
- 2021-04-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 16
- Registration Number
- NCT02468557
- Locations
- 🇺🇸
Dana Farber/ Harvard Cancer Institute, Boston, Massachusetts, United States
🇺🇸Greenville Hospital System, Greenville, South Carolina, United States
🇺🇸Indiana University Goshen Center for Cancer Care, Goshen, Indiana, United States
Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC
- Conditions
- Interventions
- First Posted Date
- 2015-06-11
- Last Posted Date
- 2019-10-25
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 567
- Registration Number
- NCT02469246
- Locations
- 🇺🇸
Pacific Oaks Medical Group, Beverly Hills, California, United States
🇺🇸Anthony Mills, MD, Inc., Los Angeles, California, United States
🇺🇸Peter J. Ruane, MD, Inc., Los Angeles, California, United States
Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3
- First Posted Date
- 2015-06-09
- Last Posted Date
- 2019-06-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 72
- Registration Number
- NCT02466516
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸University of Colorado Denver, Aurora, Colorado, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies
- Conditions
- Interventions
- First Posted Date
- 2015-05-29
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 203
- Registration Number
- NCT02457598
- Locations
- 🇬🇧
Cardiff and Vale Health Board, Clinical Research Facility, Cardiff, United Kingdom
🇺🇸Indiana University Health Goshen Center for Cancer Care, Goshen, Indiana, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States